Synonym
KX2391 Mesylate; KX2 391 Mesylate; KX2-391 Mesylate; Tirbanibulin mesylate;
IUPAC/Chemical Name
N-Benzyl-2-[5-[4-(2-morpholin-4-ylethoxy)phenyl]pyridin-2-yl]acetamide mesylate
InChi Key
JGSYRKUPDSSTCB-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H29N3O3.CH4O3S/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29;1-5(2,3)4/h1-11,20H,12-19H2,(H,28,30);1H3,(H,2,3,4)
SMILES Code
O=C(NCC1=CC=CC=C1)CC2=NC=C(C3=CC=C(OCCN4CCOCC4)C=C3)C=C2.OS(=O)(C)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
527.64
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dlott AH, Di Pasqua AJ, Spencer SA. Tirbanibulin: Topical Treatment for Actinic Keratosis. Clin Drug Investig. 2021 Sep;41(9):751-755. doi: 10.1007/s40261-021-01068-9. Epub 2021 Aug 5. PMID: 34351607.
2: Schlesinger T, Stockfleth E, Grada A, Berman B. Tirbanibulin for Actinic Keratosis: Insights into the Mechanism of Action. Clin Cosmet Investig Dermatol. 2022 Nov 16;15:2495-2506. doi: 10.2147/CCID.S374122. PMID: 36415541; PMCID: PMC9675993.
3: Markham A, Duggan S. Tirbanibulin: First Approval. Drugs. 2021 Mar;81(4):509-513. doi: 10.1007/s40265-021-01479-0. PMID: 33713299.
4: Miller AC, Adjei S, Temiz LA, Tyring SK. Tirbanibulin for the Treatment of Actinic Keratosis: A Review. Skin Therapy Lett. 2022 Jul;27(4):4-7. PMID: 35857917.
5: Dao DD, Sahni VN, Sahni DR, Balogh EA, Grada A, Feldman SR. 1% Tirbanibulin Ointment for the Treatment of Actinic Keratoses. Ann Pharmacother. 2022 Apr;56(4):494-500. doi: 10.1177/10600280211031329. Epub 2021 Jul 23. PMID: 34301153; PMCID: PMC8899810.
6: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Tirbanibulin. 2020 Dec 21. PMID: 33355728.
7: Gilaberte Y, Fernández-Figueras MT. Tirbanibulin: review of its novel mechanism of action and how it fits into the treatment of actinic keratosis. Actas Dermosifiliogr. 2022 Jan;113(1):58-66. English, Spanish. doi: 10.1016/j.ad.2021.07.006. Epub 2021 Aug 2. PMID: 35249711.
8: Gilchrest BA. Tirbanibulin: A New Topical Therapy for Actinic Keratoses With a Novel Mechanism of Action and Improved Ease of Use. Clin Pharmacol Drug Dev. 2021 Oct;10(10):1126-1129. doi: 10.1002/cpdd.1024. PMID: 34612001.
9: Tirbanibulin. Am J Health Syst Pharm. 2021 Mar 31;78(8):656-657. doi: 10.1093/ajhp/zxab094. PMID: 33787828.
10: Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040. PMID: 33567191.
